Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 27, 411–414 (1 May 2009) | doi:10.1038/nbt0509-411
Academia and the company coin
Abstract
In recent weeks, Massachusetts has been the center for a storm of controversy concerning academia's relationship with industry. Early in March, a grassroots movement involving hundreds of Harvard medical students demanded that the university reform the way it monitors and controls money the school takes in from the drug industry (Fig.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
